Spectral Medical Inc
TSX:EDT

Watchlist Manager
Spectral Medical Inc Logo
Spectral Medical Inc
TSX:EDT
Watchlist
Price: 0.495 CAD 2.06% Market Closed
Market Cap: 140m CAD
Have any thoughts about
Spectral Medical Inc?
Write Note

Spectral Medical Inc
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Spectral Medical Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Spectral Medical Inc
TSX:EDT
Depreciation & Amortization
CA$238k
CAGR 3-Years
-8%
CAGR 5-Years
-2%
CAGR 10-Years
0%
B
Bright Minds Biosciences Inc
CNSX:DRUG
Depreciation & Amortization
CA$72.5k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Depreciation & Amortization
$2.8m
CAGR 3-Years
-31%
CAGR 5-Years
-17%
CAGR 10-Years
17%
ESSA Pharma Inc
NASDAQ:EPIX
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Depreciation & Amortization
$19.5m
CAGR 3-Years
99%
CAGR 5-Years
67%
CAGR 10-Years
28%
Covalon Technologies Ltd
XTSX:COV
Depreciation & Amortization
CA$949.1k
CAGR 3-Years
12%
CAGR 5-Years
13%
CAGR 10-Years
12%
No Stocks Found

Spectral Medical Inc
Glance View

Market Cap
140m CAD
Industry
Biotechnology

Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 31 full-time employees. The firm has conducted a Phase III clinical trial for its lead product, PMX (Toraymyxin PMX-20R), which is for the treatment of patients with septic shock and endotoxemia that is measured by the Company’s Endotoxin Activity Assay (EAA). EAA and PMX are both Health Canada licensed and commercially available in Canada. The firm through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of platforms addressing renal replacement therapy (RRT) across the dialysis spectrum. SAMI is targeting the acute RRT market, while DIMI is targeting the chronic RRT market.

EDT Intrinsic Value
0.038 CAD
Overvaluation 92%
Intrinsic Value
Price

See Also

What is Spectral Medical Inc's Depreciation & Amortization?
Depreciation & Amortization
238k CAD

Based on the financial report for Sep 30, 2024, Spectral Medical Inc's Depreciation & Amortization amounts to 238k CAD.

What is Spectral Medical Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
0%

Over the last year, the Depreciation & Amortization growth was -5%. The average annual Depreciation & Amortization growth rates for Spectral Medical Inc have been -8% over the past three years , -2% over the past five years .

Back to Top